Loading clinical trials...

Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

A 3 Month Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder; Symptomatic and Functional Outcomes.

NCT00191633•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess whether changes in the symptoms of ADHD show a relationship with changes in functioning in children with ADHD treated with atomoxetine over a 3-month period.

Eligibility

Age

6 - 11 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients must have ADHD, be outpatients, who are at least 6 years of age and not more than 11 years 8 months of age at Visit 1 so that all testing will be completed before the child reaches age 12.
•Patients must have moderately severe symptoms of ADHD.
•Patients must be able to swallow study drug capsules.

Exclusion Criteria

•Patients must not have Bipolar disorder, psychosis, autism, Asperger's syndrome, pervasive developmental disorder, or seizure disorder.
•Patients must not have taken atomoxetine prior to starting the study.

Locations (19)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Calgary, Alberta, Canada

Edmonton, Alberta, Canada

Abbotsford, British Columbia, Canada

Burnaby, British Columbia, Canada

Kelowna, British Columbia, Canada

Langley, British Columbia, Canada

Vancouver, British Columbia, Canada

Winnipeg, Manitoba, Canada

Moncton, New Brunswick, Canada

Saint John, New Brunswick, Canada

Key Dates

Start Date

April 1, 2005

Completion Date

June 1, 2006

Last Updated

January 26, 2007

Enrollment

200

Estimated participants

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

Atomoxetine

DRUG

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

NCT06577779

Attention-deficit/Hyperactivity Disorder

View study

NOT_YET_RECRUITINGNA

The ADHD Kids´ Study for Children 9-12 Years of Age

NCT07379359

Attention-Deficit/Hyperactivity Disorder (ADHD)

View study

NOT_YET_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 26, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

Inclusion Criteria

Exclusion Criteria

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

The ADHD Kids´ Study for Children 9-12 Years of Age

A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD

Social Virtual-reality on Enhancing Social Interaction Skills in Children With Attention-deficit/Hyperactivity Disorder

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD